83 related articles for article (PubMed ID: 24183830)
1. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
Conticello C; Giuffrida R; Parrinello N; Buccheri S; Adamo L; Sciuto MR; Colarossi C; Aiello E; Chiarenza A; Romano A; Salomone E; Gulisano M; Giustolisi R; Di Raimondo F
Leuk Res; 2013 Dec; 37(12):1616-21. PubMed ID: 24183830
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
3. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes.
Najar M; Raicevic G; Jebbawi F; De Bruyn C; Meuleman N; Bron D; Toungouz M; Lagneaux L
Immunol Lett; 2012 Aug; 146(1-2):50-6. PubMed ID: 22575528
[TBL] [Abstract][Full Text] [Related]
4. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.
Olteanu H; Harrington AM; Kroft SH
Am J Clin Pathol; 2012 Dec; 138(6):867-76. PubMed ID: 23161721
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of CD200 on circulating CD11b+ monocytes in patients with neovascular age-related macular degeneration.
Singh A; Falk MK; Hviid TV; Sørensen TL
Ophthalmology; 2013 May; 120(5):1029-37. PubMed ID: 23410964
[TBL] [Abstract][Full Text] [Related]
6. CD200 is induced by ERK and is a potential therapeutic target in melanoma.
Petermann KB; Rozenberg GI; Zedek D; Groben P; McKinnon K; Buehler C; Kim WY; Shields JM; Penland S; Bear JE; Thomas NE; Serody JS; Sharpless NE
J Clin Invest; 2007 Dec; 117(12):3922-9. PubMed ID: 18008004
[TBL] [Abstract][Full Text] [Related]
7. CD200 and its receptors as targets for immunoregulation.
Gorczynski RM
Curr Opin Investig Drugs; 2005 May; 6(5):483-8. PubMed ID: 15912961
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma.
Aref S; Azmy E; El-Gilany AH
Hematol Oncol; 2017 Mar; 35(1):51-57. PubMed ID: 26033514
[TBL] [Abstract][Full Text] [Related]
9. CD200: a putative therapeutic target in cancer.
Moreaux J; Veyrune JL; Reme T; De Vos J; Klein B
Biochem Biophys Res Commun; 2008 Feb; 366(1):117-22. PubMed ID: 18060862
[TBL] [Abstract][Full Text] [Related]
10. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT
Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671
[TBL] [Abstract][Full Text] [Related]
11. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
Koning N; Swaab DF; Hoek RM; Huitinga I
J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
Herth I; Witzens-Harig M; Beckhove P; Hose D; Meissner T; Neuber B; Engelhardt M; Haas J; Neben K; Ho AD; Klein B; Goldschmidt H; Hundemer M
Exp Hematol; 2013 Mar; 41(3):231-40. PubMed ID: 23142220
[TBL] [Abstract][Full Text] [Related]
13. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
Guha S; Lunn JA; Santiskulvong C; Rozengurt E
Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
[TBL] [Abstract][Full Text] [Related]
14. The role of CD200-CD200R in tumor immune evasion.
Liao KL; Bai XF; Friedman A
J Theor Biol; 2013 Jul; 328():65-76. PubMed ID: 23541619
[TBL] [Abstract][Full Text] [Related]
15. CD200 expression in plasma cell myeloma.
Olteanu H; Harrington AM; Hari P; Kroft SH
Br J Haematol; 2011 May; 153(3):408-11. PubMed ID: 21275968
[No Abstract] [Full Text] [Related]
16. Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma.
Douds JJ; Long DJ; Kim AS; Li S
J Clin Pathol; 2014 Sep; 67(9):792-6. PubMed ID: 24958785
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle.
Fogar P; Basso D; Fadi E; Greco E; Pantano G; Padoan A; Bozzato D; Facco M; Sanzari MC; Teolato S; Zambon CF; Navaglia F; Semenzato G; Pedrazzoli S; Plebani M
Pancreas; 2011 Oct; 40(7):1131-7. PubMed ID: 21792088
[TBL] [Abstract][Full Text] [Related]
18. Identification of an expressed truncated form of CD200, CD200tr, which is a physiologic antagonist of CD200-induced suppression.
Chen Z; Chen DX; Kai Y; Khatri I; Lamptey B; Gorczynski RM
Transplantation; 2008 Oct; 86(8):1116-24. PubMed ID: 18946351
[TBL] [Abstract][Full Text] [Related]
19. CD200 is a new prognostic factor in multiple myeloma.
Moreaux J; Hose D; Reme T; Jourdan E; Hundemer M; Legouffe E; Moine P; Bourin P; Moos M; Corre J; Möhler T; De Vos J; Rossi JF; Goldschmidt H; Klein B
Blood; 2006 Dec; 108(13):4194-7. PubMed ID: 16946299
[TBL] [Abstract][Full Text] [Related]
20. The adaptor protein NTAL enhances proximal signaling and potentiates corticosteroid-induced apoptosis in T-ALL.
Svojgr K; Kalina T; Kanderova V; Skopcova T; Brdicka T; Zuna J
Exp Hematol; 2012 May; 40(5):379-85. PubMed ID: 22269118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
